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Objective. To evaluate the efficacy and safety of ataci-
cept, an antagonist of B lymphocyte stimulator/APRIL–
mediated B cell activation, in patients with systemic
lupus erythematosus (SLE).
Methods. ADDRESS II is a 24-week, multicenter,
randomized, double-blind, placebo-controlled, parallel-
arm, phase IIb study evaluating the safety and efficacy
of atacicept in patients with SLE (ClinicalTrials.gov
identifier NCT01972568). Patients with active, autoanti-
body-positive SLE receiving standard therapy were ran-
domized (1:1:1) to receive atacicept (75 mg or 150 mg)
or placebo for 24 weeks. The primary end point was the
SLE responder index 4 (SRI-4) at week 24.
Results. The intent-to-treat (ITT) population
included 306 patients. There was a trend toward an
improved SRI-4 response rate with atacicept 75 mg
(57.8%; adjusted odds ratio [OR] 1.78, P = 0.045) and
150 mg (53.8%; adjusted OR 1.56, P = 0.121) at week 24
as compared with placebo (44.0%) (primary analysis;
using the screening visit as baseline). In a prespecified
sensitivity analysis using study day 1 as baseline, a signif-
icantly larger proportion of patients receiving atacicept
75 mg and 150 mg achieved an SRI-4 response at week 24
compared with placebo. In predefined subpopulations
with high levels of disease activity (HDA) at baseline,
serologically active disease, or both, statistically signifi-
cant improvements in the SRI-4 and SRI-6 response rates
were seen with atacicept versus placebo. A severe risk of
disease flare was reduced with atacicept therapy in both
the ITT and the HDA populations. The risks of serious
adverse events and serious or severe infection were not
increased with atacicept as compared with placebo.
Conclusion. Atacicept treatment showed evidence
of efficacy in SLE, particularly in HDA and serologically
active patients. Reductions in disease activity and severe
flare were observed with atacicept treatment, with an
acceptable safety profile.
Systemic lupus erythematosus (SLE) is a multisys-
tem autoimmune disease with a fluctuating disease course
characterized by sporadic, unpredictable disease flares
(1–3). Standard treatments include antimalarial, cortico-
steroid, and immunosuppressive drugs (4). Despite im-
proved understanding of the disease process, there
remains a significant unmet need for new treatment
because of the continued high risk of death and progres-
sive organ damage (5–7). The long-term burden of disease
symptoms and toxic effects of immunosuppressive thera-
pies also significantly affects quality of life (8–10).
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Elevated serum levels of the cytokines B lympho-
cyte stimulator (BLyS) and APRIL in SLE patients corre-
late with both disease activity (11,12) and autoantibody
production (13–16). These factors are therefore promis-
ing targets for new investigational therapies. The BLyS
inhibitor belimumab has demonstrated efficacy and
safety in phase III studies in SLE (17,18) and is approved
for treating patients with active disease. Efficacy of ataci-
cept, the dual APRIL/BLyS inhibitor, was suggested by
the APRIL SLE study, which also confirmed its biologic
activity in reducing total B cell, plasma cell, and serum
immunoglobulin levels in SLE patients (19,20).
We report herein the findings of ADDRESS II,
a randomized, placebo-controlled phase IIb study of
weekly doses of atacicept (75 or 150 mg) versus pla-
cebo in patients with active, autoantibody-positive SLE
receiving standard therapy (ClinicalTrials.gov identifier
NCT01972568).
PATIENTS AND METHODS
Study design. In this 24-week, multicenter, random-
ized, double-blind, placebo-controlled, parallel-arm, phase IIb
study, patients with SLE receiving standard therapy were
assigned to once-weekly subcutaneous injections of placebo or
atacicept, 75 or 150 mg. The study included a screening period
of up to 4 weeks, a treatment period of 24 weeks (reported
herein), and a safety follow-up period of 24 weeks (see Supple-
mentary Figure 1, available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40360/
abstract). A long-term extension was offered as part of a
separate protocol (see Supplementary Figure 2, available
at http://onlinelibrary.wiley.com/doi/10.1002/art.40360/abstract).
The data reported herein were generated by the ADDRESS II
study investigators in Latin America, Asia, South Africa,
Europe, UK, and the US.
Prednisone-equivalent corticosteroid dosages could be
adjusted during screening (up to 40 mg/day) but had to be ≤30
mg/day and no more than the dosage at the screening visit by
week 4, except that patients receiving <7.5 mg/day at screening
could be taking as much as 7.5 mg/day at week 4. Dosage taper-
ing was encouraged during weeks 5–16. One corticosteroid res-
cue with ≤30 mg/day was allowed, but the dosage had to be
reduced to the dosage at week 4 within 7 days. The dosage at
week 16 remained stable during weeks 17–24.
Single immunosuppressive or immunomodulatory
drugs and/or an antimalarial drug were permitted. We excluded
patients who had received treatment with other investigational
agents within the previous 3 months, within a period of 5 half-
lives of that drug from the screening visit, or per the washout
requirement from the previous protocol, whichever was long-
est. Patients who had received belimumab (or other anti-BLyS
therapy), rituximab, ocrelizumab, or other B cell–directed
biologic drug within 1 year before the screening visit were
excluded. Background therapy had to remain stable during the
screening and treatment periods. Use of nonpermitted medici-
nes or therapies required discontinuation of atacicept and was
considered a treatment failure (for details, see Supplementary
Text 1, available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40360/abstract.)
Baseline was defined as the screening visit for assessments
of disease activity and as treatment day 1 for all other assess-
ments. Interim safety and disease activity data were regularly
monitored by an independent Data Safety Monitoring Board.
Eligibility criteria. Eligible patients were age ≥18 years
with at least moderately active SLE, as defined by an SLE Dis-
ease Activity Index 2000 (SLEDAI-2K) score of ≥6, met at least
4 of the American College of Rheumatology revised classifica-
tion criteria for SLE (21,22), had a disease duration of ≥6
months, and were positive for antinuclear antibody (titer ≥1:80
on HEp-2 cell substrate) and/or anti–double-stranded DNA
(anti-dsDNA) antibody (≥30 IU/ml) at screening. Up-to-date
vaccinations against Streptococcus pneumoniae and influenza
virus were required (could be given during screening). Patients
with severe glomerulonephritis (urine protein-to-creatinine ratio
>2.0 mg/mg and/or estimated glomerular filtration rate <40 ml/
minute/1.73 m2) and those with major central nervous system
manifestations were excluded. (For further eligibility criteria, see
Supplementary Text 2, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40360/abstract.)
All patients provided written informed consent. The
study was performed in accordance with the Declaration of
Helsinki, the International Conference on Harmonisation
Note for Guidance on Good Clinical Practice (ICH Topic E6,
1996), and applicable regulatory requirements. All study sites
received approval for the study from their local ethics board.
Randomization. An interactive web response system
was used to randomize the patients 1:1:1 to either of 3 study
arms. Randomization was stratified according to the SLEDAI-
2K total score (6–9 versus ≥10), race (black/African American
versus other), and use of mycophenolate mofetil at screening.
Assessment of end points. The primary end point was
the SLE Responder Index 4 (SRI-4) (17,18) without clinically
significant use of nonpermitted medication or treatment at
week 24 compared with the screening visit. The SRI-4 is a
composite end point that includes SLEDAI-2K score ≥4 point
reduction; <10% increase in physician’s global assessment; no
new organ with British Isles Lupus Assessment Group
(BILAG) [2004] A (severe) disease, and no more than 1 new
BILAG B (moderate) organ score.
Key secondary end points were corticosteroid dosage
reduction and patient’s global assessment of change at 24
weeks. (For complete details, see Supplementary Text 3, avail-
able at http://onlinelibrary.wiley.com/doi/10.1002/art.40360/
abstract.) Other disease activity end points were severe flares,
as assessed by the Safety of Estrogens in Lupus Erythemato-
sus National Assessment (SELENA) version of the SLEDAI
(the SELENA–SLEDAI flare index [SFI]) or by a new
BILAG A (severe) manifestation (23). An evaluation of the
SRI-6 in the predefined high disease activity (HDA) subpopu-
lation (SLEDAI-2K score ≥10 at screening) was performed.
Assessment of biomarkers. Biomarker assessments
included serum concentrations of IgG, IgM, and IgA, comple-
ment C3 and C4 (measured using Tina-Quant complement C4
and C3c tests; Roche Diagnostics), and anti-dsDNA antibodies
(measured by enzyme-linked immunosorbent assay; Phadia).
Assessment of safety. Safety was assessed according to
the findings on the physical examination, vital signs measure-
ments, electrocardiograms, and clinical laboratory tests. Reports
of adverse events (AEs) and serious AEs were also evaluated.
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Statistical analysis. Assuming a 30% response rate
with placebo and a 2-sided alpha value of 0.05, a total of 93
patients per arm would provide 80% power to detect a 20%
absolute difference in the proportion of patients achieving an
SRI-4 response for each of the 2 active drug groups versus
placebo. With the 1:1:1 randomization ratio, the planned total
sample size was therefore 279.
Data analysis was planned for the following popula-
tions: intent-to-treat (ITT; all randomized patients), modified
ITT (all randomized patients who received at least 1 dose of
study medication, whether atacicept or placebo), safety (all
randomized patients who received at least 1 dose of study
medication, whether atacicept or placebo, and were analyzed
according to actual treatment received), and HDA (a sub-
group of the modified ITT population with a SLEDAI-2K
score of ≥10 at screening). The primary efficacy analysis was
performed using the modified ITT population. Step-down
sequential testing was used to control for multiplicity in test-
ing the 2 atacicept doses. The atacicept 150-mg arm was to
be first compared with placebo (primary analysis; 2-sided a =
0.05) and, if statistically significant, the atacicept 75-mg arm
was compared with placebo. Prespecified sensitivity analyses








Age, mean  SD years 40  13.0 37  11.2 39  11.6
Sex, no. (%)
Female 90 (90) 93 (91.2) 97 (93.3)
Male 10 (10) 9 (8.8) 7 (6.7)
Race, no. (%)
White 78 (78.0) 72 (70.6) 66 (63.5)
Black/African American 5 (5.0) 6 (5.9) 9 (8.7)
Asian 7 (7.0) 15 (14.7) 14 (13.5)
Native American or Alaska Native 4 (4.0) 3 (2.9) 4 (3.8)
Native Hawaiian or other Pacific Islander 1 (1.0) 0 (0.0) 0 (0.0)
Other 5 (5.0) 6 (5.9) 11 (10.6)
Hispanic or Latino ethnicity, no. (%) 57 (57.0) 51 (50.0) 45 (43.3)
Geographic region
Europe 26 (26.0) 23 (22.5) 30 (28.8)
Asia 5 (5.0) 12 (11.8) 10 (9.6)
North America 22 (22.0) 21 (20.6) 20 (19.2)
Central and South America 47 (47.0) 46 (45.1) 44 (42.3)
Disease duration, mean  SD years 6.79  7.648 6.77  6.854 6.93  6.954
SLEDAI-2K
Mean  SD score 10  2.8 10  3.3 10  3.0
No. (%) with score of ≥10 52 (52.0) 54 (52.9) 51 (49.0)
Physician’s global assessment score, mean  SD 1.50  0.452 1.42  0.532 1.46  0.460
BILAG 2004 1A or 2B score, no. (%) 60 (60.0) 57 (55.9) 72 (69.2)
Serologically active disease† 29 (29.0) 29 (28.4) 26 (25.0)
Medications
Corticosteroid (prednisone equivalent)
Mean  SD dose, mg/day 9.40  7.503 10.18  8.898 9.41  7.417
No. (%) taking >7.5 mg/day 54 (54.0) 56 (54.9) 55 (52.9)
Antimalarial drug, no. (%) 78 (78.0) 75 (73.5) 80 (76.9)
Immunosuppressive drug, no. (%)
Azathioprine 20 (20.0) 20 (19.6) 21 (20.2)
Methotrexate 18 (18.0) 12 (11.8) 13 (12.5)
Mycophenolate mofetil 16 (16.0) 16 (15.7) 18 (17.3)
Other‡ 0 (0.0) 1 (1.0) 3 (2.9)
Serum biomarkers
ANA titer ≥1:80, no. (%) 96 (96.0) 99 (97.1) 98 (94.2)
Anti-dsDNA ≥15 IU/ml, no. (%) 47 (47.0) 51 (50.0) 49 (47.1)
Complement, no. (%) under LLN
C3 <0.9 gm/liter 32 (32.0) 36 (35.3) 33 (31.7)
C4 <0.1 gm/liter 19 (19.0) 16 (15.7) 21 (20.2)
IgG, mean  SD gm/liter 14.2  4.64 13.9  4.66 15.0  5.52
* The intent-to-treat population consisted of all patients randomized into the study who received at least 1 dose
of study medication. SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2000; BILAG = British
Isles Lupus Assessment Group; ANA = antinuclear antibody; LLN = lower limit of normal.
† Anti–double-stranded DNA (anti-dsDNA) antibody positivity (≥15 IU/ml) and low levels of complement (<0.9
gm/liter of C3 and/or <0.1 gm/liter of C4).
‡ Other immunosuppressive drugs were cyclosporine and leflunomide.
268 MERRILL ET AL
for the primary end point were conducted as follows: 1) using
treatment day 1 as baseline (rather than the screening visit),
2) in the HDA subpopulation, and 3) in patient subgroups
with serologically active disease (anti-dsDNA antibody level
≥15 IU/ml and low levels of complement [C3 <0.9 gm/liter
and/or C4 <0.1 gm/liter]).
Analyses of key secondary end points (corticosteroid
dosage reduction and patient’s global assessment of change at
week 24) were performed in a hierarchical manner (first, the
150-mg dose versus placebo, then, the 75-mg dose versus pla-
cebo) to control for overall Type I error (2-sided a = 0.05)
but became exploratory if the primary end point was not met
for either atacicept dose. All other secondary end points were
analyzed descriptively using appropriate summary statistics.
All treatment effect tests were conducted at a 2-sided
alpha level of 0.05. P values and 2-sided 95% confidence inter-
vals (95% CIs) are presented where applicable. Binary end
points were analyzed using logistic regression, adjusted for ran-
domization stratification factors. Continuous end points were
analyzed using analysis of covariance, adjusted for the baseline
value and randomization stratification factors. Time to severe
SLE flares was defined according to the BILAG and SFI flare
indices separately, and analyzed using a Cox proportional haz-
ard regression model adjusted for baseline stratification factors.
Patients not experiencing severe flare were censored at time of
last treatment.
RESULTS
Study population. A total of 306 patients were
randomized to receive either placebo (n = 100), atacicept
75 mg (n = 102), or atacicept 150 mg (n = 104). Disposi-
tion of the study patients is shown in Supplementary Fig-
ure 3 (available at http://onlinelibrary.wiley.com/doi/10.
1002/art.40360/abstract). All randomized patients (n =
306, the ITT population) received at least 1 dose of ataci-
cept or placebo and were included in the modified ITT
and safety analyses. Forty-four patients (14.4%) discontin-
ued treatment prematurely after randomization (16.0% of
the placebo group, 15.7% of the atacicept 75-mg group,
and 11.5% of the atacicept 150-mg group). The main rea-
sons for discontinuation were AEs (16 patients [36.4%])
or the patient’s decision to withdraw (n = 16 patients
[36.4%]). One patient was lost to follow-up.
The demographic features, disease characteristics
and severity, and background medications at baseline
were similar between groups, except that more patients
in the atacicept 150-mg group than in the 75-mg group
had BILAG 2004 1A or 2B scores at screening (Table 1).
BILAG A and B organ system manifestations were
mainly mucocutaneous and musculoskeletal (Supple-
mentary Table 1, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40360/abstract), and the most com-
mon SLEDAI-2K disease manifestations included arthri-
tis, rash, and low levels of complement (Supplementary
Table 2, available at http://onlinelibrary.wiley.com/doi/
10.1002/art.40360/abstract). In the ITT population, 84
patients (27.5%) had serologically active disease.
The HDA subpopulation included 158 patients
(51.6%). Baseline BILAG A and B organ system and
SLEDAI-2K manifestations were mainly balanced across
treatment arms, although more patients in the atacicept
150-mg group than the 75-mg group experienced BILAG
B mucocutaneous (76.5% versus 58.2%) and muscu-
loskeletal (66.7% versus 56.4%) manifestations (Supple-
mentary Table 1). Other clinical features of SLE in the
HDA subpopulation were comparable to those in the ITT
population, except for the following SLEDAI-2K manifes-
tations, which were more frequent in HDA patients: low
complement levels (50.0% versus 35.6%), anti-dsDNA
antibody positivity (67.7% versus 48.0%), and proteinuria
(14.6% versus 8.2%) (Supplementary Tables 1 and 2).
Daily doses of corticosteroids at screening were similar in
the ITT and HDA populations (Supplementary Table 3,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40360/abstract).
SRI responses. SRI-4 response. In the primary
efficacy analysis, there was a trend toward an improved
SRI-4 response rate at week 24 with atacicept 75 mg
(57.8%; adjusted odds ratio [OR] 1.78 [95%CI 1.01–3.12],
P = 0.045) and atacicept 150 mg (53.8%; adjusted OR 1.56
[95% CI 0.89–2.72], P = 0.121) versus placebo (44.0%)
(Table 2). Differences in treatment response versus pla-
cebo were observed from around week 16 (Figure 1A).
Since the primary end point was not met, all other
analyses are considered exploratory. In a prespecified sen-
sitivity analysis using day 1 as baseline, both atacicept
doses improved SRI-4 response rates at week 24 in the
ITT population (P < 0.05 for each comparison) (Supple-
mentary Figure 4, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40360/abstract). The serologically active
patient subgroup achieved significantly higher SRI-4
response rates with both 75 mg (62.1% [adjusted OR
5.96 (95% CI 1.85–19.15)], P = 0.003) and 150 mg
(61.5% [adjusted OR 7.49 (95% CI 2.12–26.44)], P =
0.002) of atacicept versus placebo (24.1%) at week 24
(Table 2). Furthermore, dose-dependent improvements
in SRI-4 response rates were seen in the HDA subpopu-
lation, with atacicept 150 mg improvement (62.7%)
being significantly higher than placebo (42.3%) at week
24 (adjusted OR 2.44 [95% CI 1.09–5.44], P = 0.029)
(Table 2). Improvement in treatment response was
observed from week 4, and this increased to the end of
treatment (Figure 1B).
SRI-6 response. In the HDA subpopulation, an
SRI-6 response at week 24 occurred more frequently with
atacicept 150 mg (54.9% [adjusted OR 3.31 (95% CI
1.44–7.61)], P = 0.005) versus placebo (28.8%) (Table 2).
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Table 2. SRI responder rates at week 24*
Population
Response rate, no. (%)
Atacicept 75 mg versus
placebo response
















OR (95% CI) P
ITT population†
No. of patients 100 102 104
SRI-4 score 44 (44.0) 59 (57.8) 56 (53.8) 13.8 1.78 (1.01–3.12) 0.045 9.8 1.56 (0.89–2.72) 0.121
SRI-6 score 30 (30.0) 32 (31.4) 38 (36.5) 1.4 1.08 (0.59–1.98) 0.810 6.5 1.44 (0.79–2.62) 0.230
No. serologically active 29 29 26
SRI-4 score 7 (24.1) 18 (62.1) 16 (61.5) 37.9 5.96 (1.85–19.15) 0.003 37.4 7.49 (2.12–26.44) 0.002
SRI-6 score 4 (13.8) 13 (44.8) 12 (46.2) 31.0 5.48 (1.49–20.13) 0.010 32.4 6.45 (1.66–25.06) 0.007
HDA population‡
No. of patients 52 55 51
SRI-4 score 22 (42.3) 33 (60.0) 32 (62.7) 17.7 2.11 (0.97–4.59) 0.060 20.4 2.44 (1.09–5.44) 0.029
SRI-6 score 15 (28.8) 24 (43.6) 28 (54.9) 14.8 1.98 (0.88–4.46) 0.098 26.1 3.31 (1.44–7.61) 0.005
No. serologically active 24 25 20
SRI-4 score 6 (25.0) 16 (64.0) 13 (65.0) 39.0 5.97 (1.70–21.02) 0.005 40.0 7.72 (1.88–31.67) 0.005
SRI-6 score 4 (16.7) 12 (48.0) 11 (55.0) 31.3 4.88 (1.28–18.64) 0.020 38.3 7.31 (1.71–31.28) 0.007
* The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) score represents a ≥4-point reduction, and the SRI-6 score represents a
≥6-point reduction, in the score on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLEDAI,
with no new BILAG domain score or no more than 1 new BILAG B domain score, and no deterioration from baseline of >0.3 points in the
physician’s global assessment. Serologically active was defined as the anti-dsDNA antibody positivity (≥15 IU/ml) and low levels of comple-
ment (<0.9 gm/liter of C3 and/or <0.1 gm/liter of C4). Adjusted odds ratios (ORs), 95% confidence intervals (95% CIs), and P values were
estimated from a logistic regression model and adjusted for prespecified covariates. See Table 1 for other definitions.
† The intent-to-treat (ITT) population consisted of all patients randomized into the study who received at least 1 dose of study medication.






















ITT population (n = 306)






















HDA  population (n = 158)
*




Figure 1. Effect of atacicept on the disease response of patients with systemic lupus erythematosus (SLE), as determined by the SLE Responder
Index 4 (SRI-4). A, Proportion of SRI-4 responders in the intent-to-treat (ITT) population. B, Proportion of SRI-4 responders in the high disease
activity (HDA) subpopulation. Values at the right are the effect size (D) for the indicated treatment groups. * = P < 0.05 versus placebo. D1=
treatment day 1.
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Separation of treatment effects was observed as early as
week 8 and attained a significant difference by week 16
(Figure 2B). The effect was not significant at week 24 in
the ITT population (Figure 2A). The treatment effect
size was pronounced in the patients with serologically
active disease, both in the ITT population and in the
HDA population (Table 2 and Figures 2C and D). Simi-
larly, a subgroup of patients within the HDA subpopula-
tion who were positive for anti-dsDNA antibody, had low
complement levels, or both at baseline achieved a 30.6%
increase in the SRI-6 response rate with atacicept 150 mg
treatment versus placebo.
Modified SRI-4 and SRI-6 response rates excluding
anti-dsDNA antibodies and complement levels. Although
the treatment effect size (Δ) for atacicept versus placebo
was lower after these SLEDAI serologic parameters were
excluded from the calculation of improvement in the
SLEDAI-2K score, differences between atacicept 150 mg
and placebo were still apparent in the HDA subpopula-
tion. For the modified SRI-4, the values ranged from
D16.5% in HDA patients to D23.2% in HDA patients
who had anti-dsDNA antibodies or low complement
levels at screening. For the modified SRI-6, the values
ranged from D18.2% in HDA patients to D21.8% in
HDA patients who had anti-dsDNA antibodies or low
complement levels at screening (Supplementary Table 4,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40360/abstract).
Severe disease flares. In the ITT population, the
incidence of severe disease flares was reduced with
atacicept 75 mg according to the incidence of new
BILAG A manifestation (Figure 3A) and with atacicept
150 mg according to the SFI (2.9% versus 14.0% with
placebo; hazard ratio (HR) 0.18 [95% CI 0.05–0.62],
P = 0.002). The impact on disease flare was more pro-
nounced in the HDA subpopulation: both atacicept
doses led to reductions in severe flares according to
both the incidence of a new BILAG A manifestation
(Figure 3B) and the SFI (with 150 mg, HR 0.19 [95%
CI 0.05–0.68], P = 0.004; with 75 mg, HR 0.33 [95% CI
0.12–0.94], P = 0.029) versus placebo (25.0%).
Findings of key secondary end points. Atacicept
75 mg or 150 mg did not significantly increase the propor-
tion of patients achieving a corticosteroid dosage reduc-
tion to ≤7.5 mg/day at week 24 versus placebo (17.9%,
11.3%, and 18.9%, respectively) in patients whose corti-
costeroid dosage was ≥10 mg/day at screening. Similarly,
with atacicept versus placebo, no difference was observed
in the proportion of patients reporting the following 7 cat-
egories of change in the patient’s global assessment: very
much improved, much improved, minimally improved, no
change, minimally worse, much worse, or very much
worse at week 24 since beginning the treatment (data not
shown).
Levels of biomarkers. In patients with low levels
of serum complement C3 (n = 101) or C4 (n = 56) at



































































































Figure 2. Effect of atacicept on the disease response of patients with systemic lupus erythematosus (SLE), as determined by the SLE Responder Index
6 (SRI-6). A, Proportion of SRI-6 responders in the intent-to-treat (ITT) population. B, Proportion of SRI-6 responders in the high disease activity
(HDA) subpopulation. C, Proportion of SRI-6 responders in the serologically active subgroup (anti–double-stranded DNA [anti-dsDNA] antibody posi-
tive [≥15 IU/ml] and low levels of complement) of the ITT population. D, Proportion of SRI-6 responders in the serologically active subgroup (anti-
dsDNA antibody positive and low levels of complement) of the HDA subpopulation. * = P < 0.05 versus placebo. D1 = treatment day 1.
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baseline, atacicept at either dosage led to a steady
increase in serum C3 or C4 levels, respectively, from week
4 until week 24, but in the placebo group, the levels
remained similar to baseline throughout the treatment
period. At week 24, the median percentage increase in
the serum C3 levels compared with baseline (treatment
day 1) was 5.3% with atacicept 75 mg and 22.1% with
atacicept 150 mg versus 1.5% with placebo. The median
percentage increase in the serum C4 level was 64.5% with
atacicept 75 mg and 128.6% with atacicept 150 mg (Fig-
ures 4A and B). In patients with a low C3 and/or C4 level
at baseline (n = 109), a normalized C3 and C4 level at
week 24 was achieved in 52.6% and 30.6% taking ataci-
cept 150 mg and 75 mg, respectively, versus 17.1% taking
placebo.
In patients with anti-dsDNA antibodies at baseline
(n = 147), both atacicept dosages reduced anti-dsDNA
antibody levels over time. At week 24, the median percent-
age change versus baseline was –23.6% with atacicept 75
mg and –28.2% with atacicept 150 mg. Anti-dsDNA anti-
body levels increased by a median of 16.0% with placebo
treatment (Figure 4C). Treatment with atacicept 150 mg
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HDA population (n = 158)
Weeks
0 4 8 12 16 20 24
Atacicept 75 mg vs placebo:
HR, 0.24 (95% CI 0.07–0.87; P = 0.019)
Atacicept 150 mg vs placebo:
HR, 0.54 (95% CI 0.21–1.39; P = 0.198)
Atacicept 75 mg vs placebo:
HR, 0.08 (95% CI 0.01–0.59; P = 0.002)
Atacicept 150 mg vs placebo:
HR, 0.32 (95% CI 0.10–0.99; P = 0.038)
A
B
Figure 3. Kaplan-Meier analysis of time to first severe flare according to scores on the British Isles Lupus Assessment Group (BILAG) A grade
manifestations. A, Intent-to-treat (ITT) population. B, High disease activity (HDA) subpopulation. Numbers across the bottom of the x-axes are
the numbers of patients at the indicated time points. HR = hazard ratio; 95% CI = 95% confidence interval.
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and 75 mg increased the likelihood of not having a positive
anti-dsDNA antibody result at week 24 as compared with
placebo (30.6%, 19.6%, and 2.1%, respectively).
At week 24, serum IgG levels were reduced from
baseline by ~30% and 25% with atacicept 150 and 75 mg,
respectively (Figure 4D and Supplementary Figure 5,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40360/abstract). There were no incidents of severe
hypogammaglobulinemia (serum IgG <3 gm/liter). The
median percentage reduction in the serum levels of IgA
(~50% with 150 mg and ~45% with 75 mg) and IgM
(~70% with 150 mg and ~60% with 75 mg) compared with
baseline were of greater magnitude than the median per-
centage reduction in the serum level of IgG (Supplemen-
tary Figure 6, available at http://onlinelibrary.wiley.com/
doi/10.1002/art.40360/abstract).
Safety. Rates of treatment-emergent AEs (TEAEs)
were higher with atacicept 75 mg and 150 mg versus pla-
cebo (81.4%, 80.8%, and 72.0%, respectively). The most
commonly reported AEs across treatment arms were injec-
tion site reactions, injection site pain, urinary tract infec-
tions, upper respiratory tract infections, and diarrhea
(Supplementary Table 5, available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40360/abstract). Incidence rates
of TEAEs were similar with atacicept 75 and 150 mg and
placebo, except for upper respiratory tract infections (9.8%,
12.5%, and 3.0%, respectively) and diarrhea (6.9%, 11.5%,
and 5.0%), which were more common with atacicept, and
urinary tract infections (11.8%, 11.5%, and 17.0%), which
were more common with placebo. Other commonly
reported infections with atacicept 75 and 150 mg included
nasopharyngitis (4.9% and 6.7%), bronchitis (1.0% and
3.8%), and influenza (2.9% and 2.9%). Pneumonia
occurred in 1 patient (1.0%) in each atacicept group. There
were fewer serious TEAEs with atacicept 75 and 150 mg
than with placebo (5.8%, 8.8%, and 12.0%, respectively).
One patient treated with atacicept 150 mg (1%) reported
a serious infection, compared with 5.9% treated with
atacicept 75mg and 5.0% treated with placebo.
The incidence of TEAEs leading to treatment dis-
continuation was comparable between study arms. Severe
treatment-emergent injection site reactions were infre-
quent, occurring in 1 patient (1.0%) receiving atacicept
75 mg and 1 patient (1.0%) receiving placebo. There were
no notable differences in clinical laboratory parameters
(i.e., hematology, liver function tests) between either of
the atacicept groups and placebo. No deaths occurred
during the study. Immunogenicity was assessed predose
and postdose: 7 patients in the atacicept 75-mg group and
1 patient in the atacicept 150-mg group had measurable
antibodies to atacicept at week 24.
DISCUSSION
ADDRESS II compared the efficacy and safety of
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Figure 4. Changes in serum biomarkers over time. The median percentage change from baseline over 24 weeks is shown for A, serum comple-
ment C3 levels (C3-low patients), B, serum complement C4 levels (C4-low patients), C, anti–double-stranded DNA (anti-dsDNA) antibody levels
(anti-dsDNA antibody–positive patients), and D, serum IgG levels.
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patients with active, autoantibody-positive SLE receiving
standard treatment. The primary end point of an SRI-4
response at week 24 was not met in the ITT population,
although there was a trend toward increased response
rates with atacicept. A more robust increase in the SRI-4
response rates for both atacicept doses was observed in
the sensitivity analysis in which day 1 was used as baseline.
The treatment effect size according to the SRI-4 in the
ITT population observed with atacicept 150 mg versus
placebo (Δ9.8% [adjusted OR 1.56] and Δ14.8% [adjusted
OR 1.96] in the primary and sensitivity analyses, respec-
tively) was similar to that observed with the highest dose
of belimumab (10 mg/kg) in the 52-week BLISS-52 and
BLISS-76 studies (Δ14.0% and Δ9.7%, respectively)
(17,18). Similar to the much larger BLISS studies, this
trial was conducted on a background of standard care and
included some adjustments in the steroid dosage, which
protects the safety of the sickest subpopulations, but sup-
ports high SRI-4 response rates in the placebo group
among patients with moderate disease, a tradeoff that
may limit the effect size if there is a ceiling of response
rates for targeted treatments in a heterogeneous disease.
We analyzed response in the stratified subpopula-
tion of patients with HDA (SLEDAI-2K of ≥10 at base-
line). Major treatment effects were observed with atacicept
150 mg versus placebo according to both the SRI-4
(Δ20.4%), a measure of clinically meaningful response, and
the SRI-6 (Δ26.1%), an end point that requires a greater
response. Even with the greater threshold for an SRI-6
response in patients with severe disease, the response rate
with atacicept 150 mg remained high (54.9%). These find-
ings are consistent with the findings of subgroup analyses in
blisibimod and belimumab studies that demonstrated an
increased treatment effect in patients with HDA (24,25).
These data suggest that when the target population is
patients with HDA, there is a greater likelihood of discrimi-
nating an effective treatment from placebo, and this may
have implications for future trial designs.
Serologic activity also defined a subpopulation
with increased responsiveness to belimumab (18,24). We
observed increased treatment effect sizes for SRI-4 and
SRI-6 with atacicept in patients with serologically active
disease, both in the ITTand HDA populations, consistent
with the roles played by BLyS in B cell proliferation and
maturation, autoantibody production, and thus, disease
pathogenesis (16,26–28). Since serologic normalization
can lead to a potential 4-point improvement in the
SLEDAI score (potentially accounting for achievement of
an SRI-4 response without clinical improvement), the
extent to which serologic effects contributed to SRI
response rates in these populations was examined by
excluding serologic data from the SRI assessment.
Despite reductions in treatment effect sizes, response dif-
ferences were still pronounced, confirming that atacicept
treatment led to both clinical and serologic improve-
ments.
Consistent with the post hoc analysis of the
APRIL-SLE study, in which flare rates were reduced with
atacicept 150 mg (29), we observed reductions in the inci-
dence of new, severe BILAG A scores and SFI severe
flares with atacicept versus placebo in both the ITT popu-
lation and the HDA subpopulation. Atacicept has there-
fore demonstrated consistent flare reduction in 2 studies.
The biomarker results were comparable with those
previously observed in studies of atacicept, including the
APRIL-SLE study (29–31). Reduced serum immunoglob-
ulin and anti-dsDNA autoantibody levels and increased
complement levels were apparent soon after administra-
tion of atacicept and continued to the end of treatment.
Themagnitude of changes appeared to be greater than those
reported for agents targeting BLyS alone (17,18,25,32).
This is consistent with the role of APRIL in plasma cell
survival (33,34), antibody production, and potentially,
associated complement consumption.
The safety profile of atacicept was acceptable. Com-
pared with placebo, there was no increase in the overall fre-
quency of serious AEs or in the subset of serious infections
associated with active treatment. Reassuringly, there were
no cases of severe hypogammaglobulinemia and no deaths.
The atacicept 150 mg treatment arm of the APRIL-SLE
study was prematurely terminated as a cautionary measure,
as recommended by the Independent Data Monitoring
Committee, following 2 deaths from pulmonary infections
complicated by pulmonary alveolar hemorrhage. Although
most large clinical trials of new therapy in SLE report simi-
lar small numbers of deaths (17,18,24,25,32), several addi-
tional risk-mitigation measures were established for the
ADDRESS II study in response to these fatal infection out-
comes. These included requirements for medical monitor
review of the patients’ screening data to confirm eligibility
as well as up-to-date vaccinations against pneumococcus
and seasonal influenza (could be administered during the
screening period up to 2 weeks prior to randomization).
These measures may have minimized the risk of serious
infections in this study population.
Potential limitations of the study include the low
proportion of black/African American patients enrolled
and the 24-week duration. Future studies will be needed
to evaluate responses in patients from populations with
renal and/or central nervous system disease and popula-
tions known to be at high risk of developing lupus and
experiencing poor outcomes. More prolonged atacicept
treatment may have provided more reliable efficacy dis-
crimination, and it will be important to assess the safety of
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longer-term treatment with atacicept. Completers of this
24-week study were offered enrollment in a long-term
extension study, the results of which will be reported as
soon as they are available.
In summary, although this phase IIb study did not
meet its primary end point, there was robust discrimination
between atacicept and placebo treatments in multiple end
points, particularly in subpopulations with serologic activ-
ity and/or high levels of disease activity. There was no
increase in the risk of serious AEs, including serious infec-
tions, in patients treated with atacicept. These results sup-
port further clinical evaluation of atacicept in SLE.
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